Centene (CNC) News Today

The stock of Centene Corporation (NYSE: CNC) has seen mixed signals this week, with analyst downgrades and legal filings weighing on sentiment, while technical buy signals and a positive overweight rating offer some offsetting support. Key developments include:

• Positive Sentiment: Cantor Fitzgerald lowered its price target on CNC to $65 from $90 while maintaining an Overweight rating, suggesting conviction in the company’s medium-term prospects. Cantor Fitzgerald Lowers PT to $65
• Positive Sentiment: Seeking Alpha reports buy signals emerged after a capitulation-like sell-off, pointing to potential upside if momentum sustains. Centene: Buy Signals Emerge
• Neutral Sentiment: Wolfe Research reiterated a Peer Perform rating, indicating CNC is expected to track its healthcare sector peers. Wolfe Research Peer Perform
• Neutral Sentiment: MarketBeat’s weekly review highlights that withdrawing 2025 guidance led to a 40% pullback, yet argues valuation metrics may attract risk-tolerant investors. Why CNC Dropped 40%
• Negative Sentiment: Mizuho slashed Centene’s price target from $71 to $40 and shifted to a Neutral rating, signaling concern over the company’s growth outlook. Mizuho Cuts PT to $40
• Negative Sentiment: Morgan Stanley downgraded CNC to an Equal Weight rating and reduced its target price to $33, reflecting a more cautious view on near-term performance. MS Downgrades to Equal Weight
• Negative Sentiment: Multiple law firms—including Glancy Prongay & Murray LLP, Gainey McKenna & Egleston, and Faruqi & Faruqi—have announced securities fraud class action lawsuits against Centene for the December 2024–June 2025 period, creating legal overhang. Class Action Notices